NCT00516724CompletedPhase 1
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours
Source: ClinicalTrials.gov · Last updated 11 Apr 2025
Brief summary (registry, in English)
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 189 (actual)
- First submitted
- 13 Aug 2007
- Start date
- 22 Jun 2007
- Primary completion date
- 4 Jan 2013
- Lead sponsor
- AstraZeneca
- Diseases
- Metastatic breast cancer, Ovarian cancer
- NCT number
- NCT00516724
- EudraCT number
- 2007-000939-26
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 189
- From 22 Jun 2007 to the primary completion date, 4 Jan 2013
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry
- Major surgery with 4 weeks of entering the study and must have recovered from effects of the major surgery
- More than two previous courses of platinum-containing chemotherapy
- Heavily pre-treated patients(\> 2 courses of previous chemotherapy and/or extensive irradiation leading to bone marrow deficiency) will be excluded from the study
Who the study is looking for
- Male or female patients with a histologically or cytologically diagnosed malignant solid tumour
- Adequate bone marrow, hepatic and renal function
- Performance status of no more than 2 ( ECOG scale).
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Brussels | Belgium | Unknown status |
| Research Site Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.